Αρχική World News ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment...

ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment Across a Variety of MMRd Tumour Types

Minimal residual disease (MRD) after curative resection or chemotherapy was detected using a circulating tumour DNA (ctDNA) screen in patients with diverse tumours harbouring mismatch repair deficiency (MMRd), according to findings from a phase II study presented at the ESMO World Congress on Gastrointestinal Cancer 2021, which was held from 30 June to 3 July.

Melissa Lumish, a clinical fellow at Memorial Sloan Kettering Cancer Center in New York, NY, US reported the results on behalf of colleagues from a study (NCT03832569) evaluating the utility of ctDNA in screening patients at high risk for recurrence following surgery or adjuvant chemotherapy to identify those who would most benefit from immune checkpoint blockade treatment.

Dr. Lumish explained that, while MMRd tumours are highly sensitive to checkpoint blockade in patients with metastatic disease regardless of tumour type, the efficacy in the adjuvant setting is unknown.

In order to assess the frequency of ctDNA in patients with resected MMRd tumours the investigators  prospectively screened patients with MMRd tumours who completed standard perioperative chemotherapy and surgery.

DNA from resected tumours and matched postoperative plasma were sequenced for the detection of somatic mutations. Patients were considered to have MRD when the mutations identified in the tumour were identical to those in matched plasma DNA. Somatic tissue mutations were assessed using MSK-IMPACT and ctDNA was assessed using FoundationOne, Guardant360 or MSK-ACCESS.

Low recurrence rates observed in minimal residual disease-negative patients

Screening was performed for the presence of MRD in 94 patients. The patients had diverse tumour types; the most commonly occurring tumour types were colorectal in 53% of patients, endometrial in 20%, and oesophagogastric in 17% of patients. Small bowel cancer was present in 4%, pancreatic in 1% and other tumours in 4%. The majority of patients had stage III.

MRD was detected in 18% of cases, which represented 14 of 78 patients with viable results; some samples failed ctDNA analysis due to technical reasons.

Just one patient among the patients with MRD-negative results developed disease recurrence. The authors commented that tumour matched ctDNA alterations predicted relapse. ctDNA predicted disease-free survival (DFS) in MSI-high tumours after surgery. In 64 patients with negative ctDNA, median DFS was not reached, while in 5 patients with positive ctDNA, median DFS was 9.7 months (p < 0.0001 by log-rank test).

Conclusions

The authors commented that commercially available ctDNA predicts outcome in resected MSI-high patients. It is critical to ensure ctDNA originates from the tumour of interest, to filter clonal haematopoietic and germline abnormalities.

MRD could be identified in 18% of resected MMRd tumours using ctDNA analysis, which suggested to the investigators that ctDNA analysis is a feasible tumour agnostic approach for evaluation of the efficacy of checkpoint blockade in patients at high risk of recurrence.

They plan future studies to assess the impact of checkpoint blockade in MRD-positive patients with MMRd tumours.

No external funding was disclosed.

Reference

O-5. Janjigian Y, Lumish M, Jayakumaran G, et al. Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection. ESMO World Congress on Gastrointestinal Cancer 2021 (30 June – 3 July).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...